Horizon Kinetics Asset Management LLC Nektar Therapeutics Transaction History

Horizon Kinetics Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$3.17 - $6.17 $92,881 - $180,781	-29,300 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.16 - $13.72 $44,387 - $146,392	10,670 Added 57.27%	29,300 $158,000
Q4 2021 Feb 15, 2022	BUY	$10.83 - $18.41 $45,810 - $77,874	4,230 Added 29.38%	18,630 $252,000
Q3 2021 Nov 15, 2021	BUY	$13.07 - $18.84 $188,208 - $271,296	14,400 New	14,400 $259,000

128

111M

150K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $232M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Horizon Kinetics Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Horizon Kinetics Asset Management LLC with notifications on news.